Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphomaEnrico Derenzini, Pier Luigi Zinzani, Claudio Agostinelli et al.|Oncotarget|2015Cited by 59
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemiaAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Neil Beeharry et al.|Journal of Hematology & Oncology|2018Cited by 56
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemiaAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Ilaria Iacobucci et al.|Oncotarget|2016Cited by 42
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cellsAndrea Ghelli Luserna di Rorà, Giorgia Simonetti, Martina Ghetti et al.|Cell Biology and Toxicology|2021Cited by 28
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemiaIlaria Iacobucci, Giovanni Martinelli, Domenico Russo et al.|Journal of Hematology & Oncology|2015Cited by 28